Weekly semaglutide with closed-loop system for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You've had type 1 diabetes for one year or more.
- You've used an automated insulin pump for at least 3 months.
- You are not pregnant, planning to become pregnant, or breastfeeding.
- You haven't taken any GLP-1 drugs (like Ozempic) in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This study tests how well a diabetes medication called semaglutide works when prescribed in everyday clinical practice in Argentina. Semaglutide comes in two forms—a pill or an injection—and the study tracks how much it lowers blood sugar over one year.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.